Gainers
- View, Inc. (NASDAQ:VIEW) rose 23.2% to $1.30 in pre-market trading after declining 9% on Wednesday.
- Kaixin Auto Holdings (NASDAQ:KXIN) shares rose 16.5% to $0.6532 in pre-market trading after reporting unaudited first half 2022 financial results.
- Verb Technology Company, Inc. (NASDAQ:VERB) rose 16.1% to $0.3381 in pre-market trading. Verb Technology shares dropped around 13% on Wednesday after the company announced a $4 million registered direct offering.
- ESSA Pharma Inc. (NASDAQ:EPIX) rose 16% to $5.57 in pre-market trading after jumping 180% on Wednesday. ESSA Pharma recently highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate Cancer Foundation Scientific Retreat.
- ServiceNow, Inc. (NYSE:NOW) rose 12.4% to $412.00 in pre-market trading after the company reported better-than-expected Q3 EPS results.
- Kirkland's, Inc. (NASDAQ:KIRK) shares rose 10.8% to $4.00 in pre-market trading after declining 3% on Wednesday.
- PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) rose 10.5% to $0.1345 in pre-market trading after dropping around 10% on Wednesday.
- Teladoc Health, Inc. (NASDAQ:TDOC) shares rose 9.3% to $29.23 in pre-market trading after the company reported better-than-expected Q3 EPS and sales results.
- Healthcare Triangle, Inc. (NASDAQ:HCTI) rose 7.7% to $0.3550 in pre-market trading after dipping around 20% on Wednesday.
- OneMain Holdings, Inc. (NYSE:OMF) rose 7.5% to $35.00 in pre-market trading following upbeat quarterly earnings.
- Aegon N.V.. (NYSE:AEG) rose 7.2% to $4.63 in pre-market trading. Aegon announced plans to combine its Dutch operations with a.s.r.
- RedHill Biopharma Ltd. (NASDAQ:RDHL) rose 7.1% to $0.7140 in pre-market trading. Redhill Biopharma recently announced its oral broad-acting antiviral, Opaganib, was granted a new COVID-19 treatment patent.
- Anheuser-Busch InBev SA/NV (NYSE:BUD) shares rose 6.8% to $50.45 in pre-market trading following Q3 results.
Don’t forget to check out our premarket coverage here .
Losers
© 2026 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
To add Benzinga News as your preferred source on Google, click here.
